Ghinwa K Dumyati

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4135807/publications.pdf

Version: 2024-02-01

122 papers 14,623 citations

36 h-index 101 g-index

122 all docs 122 docs citations

times ranked

122

16469 citing authors

#	Article	IF	CITATIONS
1	Genomic Analysis of <i>Clostridioides difficile</i> in 2 Regions of the United States Reveals a Diversity of Strains and Limited Transmission. Journal of Infectious Diseases, 2022, 225, 121-129.	4.0	2
2	Epidemiology of extended-spectrum \hat{l}^2 -lactamase \hat{a} for oducing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017. Infection Control and Hospital Epidemiology, 2022, 43, 1586-1594.	1.8	8
3	"lt's like fighting a war with rocks― Nursing home healthcare workers' experiences during the COVID-19 pandemic. Infection Control and Hospital Epidemiology, 2021, 42, 1020-1021.	1.8	15
4	"There is no one to pick up the pieces― Sustainability of antibiotic stewardship programs in nursing homes. Infection Control and Hospital Epidemiology, 2021, 42, 440-447.	1.8	12
5	Antimicrobial Use in US Hospitals: Comparison of Results From Emerging Infections Program Prevalence Surveys, 2015 and 2011. Clinical Infectious Diseases, 2021, 72, 1784-1792.	5.8	48
6	Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant $\mbox{\ensuremath{\mbox{\tiny ci}}}\mbox{\ensuremath{\mbox{\tiny Enterobacterales}\ensuremath{\mbox{\tiny ci}}}\mbox{\ensuremath{\mbox{\tiny ci}}}\ens$	4.1	29
7	Urinary tract infection stewardship: A urinary antibiogram and electronic medical record alert nudging narrower-spectrum antibiotics for urinary tract infections. Antimicrobial Stewardship & Healthcare Epidemiology, 2021, 1, .	0.5	3
8	Assessment of the Appropriateness of Antimicrobial Use in US Hospitals. JAMA Network Open, 2021, 4, e212007.	5.9	59
9	Antimicrobial Use in a Cohort of US Nursing Homes, 2017. JAMA - Journal of the American Medical Association, 2021, 325, 1286.	7.4	23
10	Practices and activities among healthcare personnel with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection working in different healthcare settingsâ€"ten Emerging Infections Program sites, Aprilâ€"November 2020. Infection Control and Hospital Epidemiology, 2021, , 1-5.	1.8	3
11	Detection of CTX-M-27 \hat{l}^2 -Lactamase Genes on Two Distinct Plasmid Types in ST38 Escherichia coli from Three U.S. States. Antimicrobial Agents and Chemotherapy, 2021, 65, e0082521.	3.2	11
12	Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. New England Journal of Medicine, 2021, 385, e90.	27.0	209
13	Mandating COVID-19 Vaccine for Nursing Home Staff: An Ethical Obligation. Journal of the American Medical Directors Association, 2021, 22, 1967-1968.	2.5	10
14	Association between Socioeconomic Status and Incidence of Community-Associated <i>Clostridioides difficile</i> Infection â€" United States, 2014â€"2015. Clinical Infectious Diseases, 2021, 73, 722-725.	5.8	10
15	Public Health Importance of Invasive Methicillin-sensitive Staphylococcus aureus Infections: Surveillance in 8 US Counties, 2016. Clinical Infectious Diseases, 2020, 70, 1021-1028.	5.8	17
16	Trends in Incidence of Methicillin-resistant Staphylococcus aureus Bloodstream Infections Differ by Strain Type and Healthcare Exposure, United States, 2005–2013. Clinical Infectious Diseases, 2020, 70, 19-25.	5.8	33
17	Reducing Fluoroquinolone Use and Clostridioides difficile Infections in Community Nursing Homes Through Hospital–Nursing Home Collaboration. Journal of the American Medical Directors Association, 2020, 21, 55-61.e2.	2.5	16
18	Epidemiology of Antibiotic Use for Urinary Tract Infection in Nursing Home Residents. Journal of the American Medical Directors Association, 2020, 21, 91-96.	2.5	20

#	Article	IF	Citations
19	Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013–2015. Journal of General Internal Medicine, 2020, 35, 412-419.	2.6	6
20	Assessment of Health Care Exposures and Outcomes in Adult Patients With Sepsis and Septic Shock. JAMA Network Open, 2020, 3, e206004.	5.9	38
21	Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant Pseudomonas aeruginosa Collected Through the Emerging Infections Program. Infection Control and Hospital Epidemiology, 2020, 41, s513-s514.	1.8	0
22	Genomic Surveillance of Ceftriaxone-Resistant Escherichia coli in Western New York Suggests the Extended-Spectrum Î ² -Lactamase blaCTX-M-27 Is Emerging on Distinct Plasmids in ST38. Frontiers in Microbiology, 2020, 11, 1747.	3.5	16
23	Does Universal Testing for COVID-19 Work for Everyone?. Journal of the American Medical Directors Association, 2020, 21, 1525-1532.	2.5	11
24	Prescriber perceptions of fluoroquinolones, extended-spectrum cephalosporins, and <i>Clostridioides difficile</i> infection. Infection Control and Hospital Epidemiology, 2020, 41, 914-920.	1.8	8
25	A Structured Tool for Communication and Care Planning in the Era of the COVID-19 Pandemic. Journal of the American Medical Directors Association, 2020, 21, 943-947.	2.5	34
26	Documentation of acute change in mental status in nursing homes highlights opportunity to augment infection surveillance criteria. Infection Control and Hospital Epidemiology, 2020, 41, 848-850.	1.8	3
27	Trends in U.S. Burden of <i>Clostridioides difficile</i> Infection and Outcomes. New England Journal of Medicine, 2020, 382, 1320-1330.	27.0	480
28	Antibiotic Prescribing in New York State Medicare Part B Beneficiaries Diagnosed With Cystitis Between 2016 and 2017. Open Forum Infectious Diseases, 2020, 7, ofz544.	0.9	5
29	Do Clean Common Areas Save Lives?. Journal of the American Geriatrics Society, 2020, 68, 460-462.	2.6	0
30	Unprecedented solutions for extraordinary times: Helping long-term care settings deal with the COVID-19 pandemic. Infection Control and Hospital Epidemiology, 2020, 41, 729-730.	1.8	32
31	Evaluation of viral co-infections among patients with community-associated Clostridioides difficile infection. PLoS ONE, 2020, 15, e0240549.	2.5	2
32	Characteristics Associated with Death in Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> , United States, 2012–2017. Infection Control and Hospital Epidemiology, 2020, 41, s59-s60.	1.8	0
33	Genomic analysis of Clostridioides difficile in two regions reveals a diversity of strains and limited transmission. Infection Control and Hospital Epidemiology, 2020, 41, s237-s238.	1.8	0
34	Appropriateness of Initiating Antibiotics for Urinary Tract Infection Among Nursing Home Residents. Infection Control and Hospital Epidemiology, 2020, 41, s127-s128.	1.8	0
35	Molecular Typing of Invasive <i>Staphylococcus aureus</i> from the Emerging Infections Program (EIP) Using Whole-Genome Sequencing. Infection Control and Hospital Epidemiology, 2020, 41, s71-s72.	1.8	0
36	Characterization of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Enterobacteriaceae, United States, 2015–2017. Infection Control and Hospital Epidemiology, 2020, 41, s465-s466.	1.8	0

3

#	Article	IF	Citations
37	Area-Based Socioeconomic Status Measures and Incidence of Community-Associated ESBL-Producing Enterobacteriaceae, 2017. Infection Control and Hospital Epidemiology, 2020, 41, s128-s129.	1.8	2
38	Improving Surveillance of Pneumonia in Nursing Homes. Infection Control and Hospital Epidemiology, 2020, 41, s290-s291.	1.8	0
39	Evaluation of Care Interactions Between Healthcare Personnel and Residents in Nursing Homes Across the United States. Infection Control and Hospital Epidemiology, 2020, 41, s36-s38.	1.8	0
40	Epidemiologic Characteristics of ESBL-Producing ST131 <i>E. coli</i> li> Identified Through the Emerging Infections Program, 2017. Infection Control and Hospital Epidemiology, 2020, 41, s214-s215.	1.8	1
41	Prevalence and Epidemiology of Healthcare-Associated Infections (HAI) in US Nursing Homes (NH), 2017. Infection Control and Hospital Epidemiology, 2020, 41, s45-s46.	1.8	1
42	Trends in <i>Staphylococcus aureus</i> Bloodstream Infections in Nursing Homes in Monroe County, New York. Infection Control and Hospital Epidemiology, 2020, 41, s417-s418.	1.8	0
43	A Tale of Two Healthcare-associated Infections:Clostridium difficileCoinfection Among Patients With Candidemia. Clinical Infectious Diseases, 2019, 68, 676-679.	5.8	3
44	Innovative methods to summarize nursing home antibiotic data. Infection Control and Hospital Epidemiology, 2019, 40, 1210-1211.	1.8	2
45	Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates. Clinical Infectious Diseases, 2019, 69, 1667-1674.	5.8	40
46	One-day point prevalence as a method for estimating antibiotic use in nursing homes. Infection Control and Hospital Epidemiology, 2019, 40, 221-223.	1.8	4
47	Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> at US Emerging Infections Program Sites, 2015. Emerging Infectious Diseases, 2019, 25, 1281-1288.	4.3	82
48	A Nationwide Screen of Carbapenem-Resistant Klebsiella pneumoniae Reveals an Isolate with Enhanced Virulence and Clinically Undetected Colistin Heteroresistance. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
49	1082. Hold the Phone: Antibiotic Prescribing Practices Associated with Nonvisit Encounters for Urinary Tract Infections (UTIs) in Urology Clinics. Open Forum Infectious Diseases, 2019, 6, S384-S384.	0.9	1
50	Racial Disparities in Invasive Methicillin-resistant <i>Staphylococcus aureus</i> Infections, 2005–2014. Clinical Infectious Diseases, 2018, 67, 1175-1181.	5.8	31
51	Trends in incidence of long-term-care facility onset Clostridium difficile infections in 10 US geographic locations during 2011-2015. American Journal of Infection Control, 2018, 46, 840-842.	2.3	19
52	1059. Staphylococcus aureus Bacteremia Treatment: Results From Pilot Surveillance in Four US States. Open Forum Infectious Diseases, 2018, 5, S316-S317.	0.9	0
53	Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. Open Forum Infectious Diseases, 2018, 5, ofy297.	0.9	22
54	363. National Burden of Candidemia, United States, 2017. Open Forum Infectious Diseases, 2018, 5, S142-S143.	0.9	31

#	Article	IF	Citations
55	479. Trends in <i>C. difficile</i> Incidence, Mortality, and NAP1/027 Strain in the Population of Monroe County, New York. Open Forum Infectious Diseases, 2018, 5, S178-S178.	0.9	0
56	490. Comparison of <i>Clostridium difficile</i> Infection Outcomes by Diagnostic Testing Method. Open Forum Infectious Diseases, 2018, 5, S181-S182.	0.9	0
57	1836. Characteristics of Nursing Homes Associated With Self-reported Implementation of Centers for Disease Control and Prevention (CDC) Core Elements of Antibiotic Stewardship. Open Forum Infectious Diseases, 2018, 5, S523-S524.	0.9	2
58	Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals. New England Journal of Medicine, 2018, 379, 1732-1744.	27.0	729
59	Carbapenem-Nonsusceptible <i>Acinetobacter baumannii</i> , 8 US Metropolitan Areas, 2012–2015. Emerging Infectious Diseases, 2018, 24, 727-734.	4.3	57
60	Burden of Invasive Methicillinâ€Resistant <i>Staphylococcus aureus</i> Infections in Nursing Home Residents. Journal of the American Geriatrics Society, 2018, 66, 1581-1586.	2.6	14
61	Measuring Antibiotic Appropriateness for Urinary Tract Infections in Nursing Home Residents. Infection Control and Hospital Epidemiology, 2017, 38, 998-1001.	1.8	27
62	Challenges and Strategies for Prevention of Multidrug-Resistant Organism Transmission in Nursing Homes. Current Infectious Disease Reports, 2017, 19, 18.	3.0	72
63	Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study. Open Forum Infectious Diseases, 2017, 4, ofx171.	0.9	67
64	Wide Range of Carbapenem-resistant Enterobacteriaceae Incidence and Trends in Emerging Infections Program Surveillance, 2012–2015. Open Forum Infectious Diseases, 2017, 4, S50-S50.	0.9	0
65	Template for an Antibiotic Stewardship Policy for Post-Acute andÂLong-Term Care Settings. Journal of the American Medical Directors Association, 2017, 18, 913-920.	2.5	45
66	Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa : Case–control study. Diagnostic Microbiology and Infectious Disease, 2017, 89, 146-150.	1.8	6
67	Socioeconomic Factors Explain Racial Disparities in Invasive Community-Associated Methicillin-Resistant Staphylococcus aureus Disease Rates. Clinical Infectious Diseases, 2017, 64, 597-604.	5.8	55
68	Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes. Open Forum Infectious Diseases, 2016, 3, ofv196.	0.9	43
69	Treatment of Clostridium difficile Infection in 10 US Geographical Locations, 2013–2014. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
70	Changes in Incidence and Strains of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections, 2005–2013. Open Forum Infectious Diseases, 2016, 3, .	0.9	4
71	Comparison of Data Collection for Healthcare-Associated Infection Surveillance in Nursing Homes. Infection Control and Hospital Epidemiology, 2016, 37, 1440-1445.	1.8	8
72	Completeness of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection Reporting From Outpatient Hemodialysis Facilities to the National Healthcare Safety Network, 2013. Infection Control and Hospital Epidemiology, 2016, 37, 205-207.	1.8	11

#	Article	IF	Citations
73	Prevalence of Antimicrobial Use and Opportunities to Improve Prescribing Practices in U.S. Nursing Homes. Journal of the American Medical Directors Association, 2016, 17, 1151-1153.	2.5	26
74	Nursing Home C. difficile Infection Rates: Is There an Association with the Frequency of Patient Transfers Between Nursing Homes and Hospitals?. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
75	The Impact of Obesity and Diabetes on the Risk of Disease and Death due to Invasive Group A <i>Streptococcus</i> Infections in Adults. Clinical Infectious Diseases, 2016, 62, 845-852.	5 . 8	29
76	Risk Factors for Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Infection After Recent Discharge From an Acute-Care Hospitalization, 2011â€"2013. Clinical Infectious Diseases, 2016, 62, 45-52.	5.8	29
77	Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United States. Emerging Infectious Diseases, 2015, 21, 1537-1542.	4.3	22
78	Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant <i>Enterobacteriaceae</i> i> Emerging Infectious Diseases, 2015, 21, 1611-1616.	4.3	60
79	Burden of <i>Clostridium difficile</i> Infection in the United States. New England Journal of Medicine, 2015, 372, 825-834.	27.0	2,313
80	Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. JAMA - Journal of the American Medical Association, 2015, 314, 1479.	7.4	272
81	Association Between Outpatient Antibiotic Prescribing Practices and Community-Associated Clostridium difficile Infection. Open Forum Infectious Diseases, 2015, 2, ofv113.	0.9	61
82	Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. Vaccine, 2015, 33, 6241-6249.	3.8	14
83	Estimating central line–associated bloodstream infection incidence rates by sampling of denominator data: A prospective, multicenter evaluation. American Journal of Infection Control, 2015, 43, 853-856.	2.3	6
84	City-Wide Collaboration to Reduce Clostridium difficile Infections. Open Forum Infectious Diseases, 2015, 2, .	0.9	2
85	887Opportunities to Improve Completeness of MRSA Bloodstream Infection Reporting From Outpatient Hemodialysis Facilities to the National Healthcare Safety Network. Open Forum Infectious Diseases, 2014, 1, S255-S255.	0.9	0
86	1800Phenotypic Definitions for Identifying Carbapenemase-Producing Carbapenem-resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2014, 1, S63-S63.	0.9	1
87	524National estimates of incidence, recurrence, hospitalization, and death of nursing home-onset Clostridium difficile infections — United States, 2012. Open Forum Infectious Diseases, 2014, 1, S16-S16.	0.9	1
88	137Developing an Approach to Evaluating the Quality of Antibiotic Prescribing in Hospitalized Patients with Community-Acquired Pneumonia (CAP) and Non-catheter Associated Urinary Tract Infection (UTI). Open Forum Infectious Diseases, 2014, 1, S70-S70.	0.9	0
89	142Retrospective, multicenter, point prevalence study of urinary tract infection (UTI) data for a city-wide antimicrobial stewardship initiative. Open Forum Infectious Diseases, 2014, 1, S72-S72.	0.9	0
90	1641Evaluation of Co-Infections among Patients with Community-Associated Clostridium difficile Infection. Open Forum Infectious Diseases, 2014, 1, S438-S439.	0.9	0

#	Article	IF	Citations
91	Clostridium difficile in the Pediatric Population of Monroe County, New York. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 183-188.	1.3	5
92	NAP1 Strain Type Predicts Outcomes From Clostridium difficile Infection. Clinical Infectious Diseases, 2014, 58, 1394-1400.	5.8	159
93	Determinants of Clostridium difficile Infection Incidence Across Diverse United States Geographic Locations. Open Forum Infectious Diseases, 2014, 1, ofu048.	0.9	37
94	Prevalence of Antimicrobial Use in US Acute Care Hospitals, May-September 2011. JAMA - Journal of the American Medical Association, 2014, 312, 1438.	7.4	281
95	Multistate Point-Prevalence Survey of Health Care–Associated Infections. New England Journal of Medicine, 2014, 370, 1198-1208.	27.0	3,009
96	Impact of Changes in Clostridium difficile Testing Practices on Stool Rejection Policies and C. difficile Positivity Rates across Multiple Laboratories in the United States. Journal of Clinical Microbiology, 2014, 52, 632-634.	3.9	28
97	The Effect of Multiple Concurrent Central Venous Catheters on Central Line–Associated Bloodstream Infections. Infection Control and Hospital Epidemiology, 2014, 35, 1140-1146.	1.8	11
98	<i>Clostridium difficile</i> Infection Among Children Across Diverse US Geographic Locations. Pediatrics, 2014, 133, 651-658.	2.1	117
99	Sustained reduction of central line–associated bloodstream infections outside the intensive care unit with a multimodal intervention focusing on central line maintenance. American Journal of Infection Control, 2014, 42, 723-730.	2.3	22
100	Vital signs: improving antibiotic use among hospitalized patients. Morbidity and Mortality Weekly Report, 2014, 63, 194-200.	15.1	208
101	Epidemiology of Community-Associated <i>Clostridium difficile</i> Infection, 2009 Through 2011. JAMA Internal Medicine, 2013, 173, 1359.	5.1	378
102	National Burden of Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Infections, United States, 2011. JAMA Internal Medicine, 2013, 173, 1970-8.	5.1	407
103	Evaluating the Accuracy of Sampling to Estimate Central Line–Days Simplification of the National Healthcare Safety Network Surveillance Methods. Infection Control and Hospital Epidemiology, 2013, 34, 221-228.	1.8	14
104	The Effect of Multiple Concurrent Central Venous Catheters on Central Line Associated Bloodstream Infections. American Journal of Infection Control, 2013, 41, S54-S55.	2.3	0
105	Community-onset invasive methicillin-resistant Staphylococcus aureus infections following hospital discharge. American Journal of Infection Control, 2013, 41, 782-786.	2.3	11
106	Characterization of Hospitalized Community-Onset Staphylococcus aureus Lower Respiratory Tract Infections Among Generally Healthy Persons 50 Years of Age or Younger. Infectious Diseases in Clinical Practice, 2013, 21, 359-365.	0.3	2
107	Trends in Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. Pediatrics, 2013, 132, e817-e824.	2.1	104
108	Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Patients on Chronic Dialysis in the United States, 2005-2011. Clinical Infectious Diseases, 2013, 57, 1393-1400.	5.8	64

#	Article	IF	CITATIONS
109	Impact of USA300 Methicillin-Resistant Staphylococcus aureus on Clinical Outcomes of Patients With Pneumonia or Central Line-Associated Bloodstream Infections. Clinical Infectious Diseases, 2012, 55, 232-241.	5.8	79
110	Burden of Clostridium difficile Infection in Long-Term Care Facilities in Monroe County, New York. Infection Control and Hospital Epidemiology, 2012, 33, 1107-1112.	1.8	54
111	Community-associatedClostridium difficileInfections, Monroe County, New York, USA. Emerging Infectious Diseases, 2012, 18, 392-400.	4.3	72
112	Device Use Ratio Measured Weekly Can Reliably Estimate Central Line–Days for Central Line–Associated Bloodstream Infection Rates. Infection Control and Hospital Epidemiology, 2011, 32, 727-730.	1.8	13
113	Differential risk of <i>Clostridium difficile</i> infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiology and Drug Safety, 2011, 20, 1035-1042.	1.9	54
114	Cumulative Antibiotic Exposures Over Time and the Risk of Clostridium difficile Infection. Clinical Infectious Diseases, 2011, 53, 42-48.	5.8	357
115	Health Care–Associated Invasive MRSA Infections, 2005-2008. JAMA - Journal of the American Medical Association, 2010, 304, 641.	7.4	385
116	Characterization of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates Collected in 2005 and 2006 from Patients with Invasive Disease: a Population-Based Analysis. Journal of Clinical Microbiology, 2009, 47, 1344-1351.	3.9	118
117	Rapid Molecular Characterization of <i>Clostridium difficile</i> and Assessment of Populations of <i>C. difficile</i> in Stool Specimens. Journal of Clinical Microbiology, 2009, 47, 2142-2148.	3.9	44
118	Usefulness of antibiogram surveillance for methicillin-resistant Staphylococcus aureus in outpatient pediatric populations. Diagnostic Microbiology and Infectious Disease, 2009, 64, 70-75.	1.8	7
119	Invasive Methicillin-Resistant <emph type="ITAL">Staphylococcus aureus</emph> Infections in the United States. JAMA - Journal of the American Medical Association, 2007, 298, 1763.	7.4	2,997
120	Community-associated Methicillin-resistant <i>Staphylococcus aureus</i> and Healthcare Risk Factors. Emerging Infectious Diseases, 2006, 12, 1991-1993.	4.3	175
121	Antivirals for Influenza. Drugs and Aging, 2002, 19, 777-786.	2.7	8
122	Practical Use of Vaccines to Prevent Infection with Influenza Virus and Streptococcus pneumoniae. BioDrugs, 1994, 2, 248-260.	0.7	2